Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (NASDAQ: CMND) has completed the initiation of all planned sites for its Phase I/IIa clinical trial in Alcohol Use Disorder (AUD), including the Yale School of Medicine's Department of Psychiatry. The company has secured all necessary preparations, including FDA approval for the Investigational New Drug (IND), Institutional Review Board (IRB) approvals, and the implementation of an Electronic Data Capture (EDC) system.

The trial will be conducted at three locations: Yale School of Medicine led by Dr. Anahita Bassir Nia, Johns Hopkins University School of Medicine, and the IMCA Center in Israel. The study will evaluate CMND-100, the company's drug candidate, which has been successfully manufactured and imported into the United States. The company is now ready to begin patient enrollment for this innovative treatment targeting alcoholism.

Clearmind Medicine Inc. (Nasdaq: CMND) has announced a live webinar titled 'Gazing Through the Crystal Ball' scheduled for May 21, 2025, at 12:00 PM ET. The event will explore the evolving landscape of psychedelic science and business, particularly focusing on FDA policies and political climate changes.

The distinguished panel features notable experts including:

• Rick Doblin, PhD - Founder and President of MAPS
• Robin Carhart-Harris, PhD - Ralph Metzner Distinguished Professor at UCSF
• Dr. Adi Zuloff-Shani - CEO of Clearmind Medicine, leading CMND-100 development for Alcohol Use Disorder
• Mark Haden - VP Business Development and UBC Adjunct Professor

The discussion will be moderated by Shannon Smadella, wellness advocate and podcast host.

Clearmind Medicine (Nasdaq: CMND) has received a Notice of Allowance from the United States Patent Office for a patent covering its MEAI treatment for binge behavior. This development strengthens the company's intellectual property portfolio and provides additional protection for their novel MEAI-based treatment.

The clinical-stage biotech company, which focuses on developing psychedelic-derived therapeutics for major under-treated health problems, views this patent allowance as a important step in supporting their future success and advancing next-generation psychedelic-derived therapeutics aimed at delivering transformative patient outcomes.

Clearmind Medicine (NASDAQ: CMND) has launched its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use Disorder (AUD), at Johns Hopkins University School of Medicine. The trial will also be conducted at Yale School of Medicine and IMCA Center in Israel.

The study aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, with preliminary efficacy assessments focusing on alcohol craving and consumption reduction. The trial represents the first clinical application of Clearmind's proprietary MEAI-based oral drug platform.

The study will be led by Jennifer Ellis, PhD, and Professor Eric Strain at Johns Hopkins. This initiative addresses a significant global health challenge, as WHO reports approximately 400 million people suffer from alcohol use disorders, with 209 million experiencing alcohol dependence. Alcohol contributes to 2.6 million deaths annually, representing 4.7% of global deaths, with 13% occurring among those aged 20-39.

Clearmind Medicine (NASDAQ: CMND) has initiated its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use Disorder (AUD), at Johns Hopkins University School of Medicine. The trial will also be conducted at Yale School of Medicine and IMCA Center in Israel.

The study aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in AUD patients, including preliminary efficacy assessments for reducing alcohol cravings and consumption. CMND-100 is a proprietary MEAI-based oral drug candidate designed to modulate reward mechanisms associated with addictive behavior.

The trial's significance is underscored by global AUD statistics: 400 million people aged 15 and older live with alcohol use disorders, with 209 million experiencing alcohol dependence. Alcohol contributes to 2.6 million deaths annually (4.7% of global deaths), with 13% occurring among ages 20-39. In the US, 15.1% of adults aged 18-25 met past-year AUD criteria according to the 2023 NSDUH.

Clearmind Medicine (Nasdaq: CMND) has announced the publication of an international patent application for novel psychedelic-based compounds, developed in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent application focuses on innovative compounds designed to treat mental health disorders and addiction.

The announcement, made on April 08, 2025, represents a significant advancement in Clearmind's mission to develop next-generation psychedelic-derived therapeutics. These new '3.0 compounds' are designed to overcome limitations of classical psychedelics while providing safe and effective solutions for under-treated mental health conditions.

The patent is part of Clearmind's exclusive worldwide licensing agreement with Yissum, encompassing the development, research, manufacturing, marketing, and commercialization of products derived from patent-pending psychedelic compound synthesis.

Clearmind Medicine (Nasdaq: CMND) has launched its Electronic Data Capture (EDC) system for its Phase I/II clinical trial evaluating a MEAI-based treatment for Alcohol Use Disorder (AUD). The EDC system represents a important operational milestone, enabling:

• Real-time, secure data collection across study sites
• Automated edit checks and validation
• Secure randomization process
• Accurate tracking of safety events
• Informed consent procedures
• Proper patient allocation between study arms

The clinical trial aims to assess the safety, tolerability, and efficacy of Clearmind's psychedelic-derived, MEAI-based compound in individuals with alcohol addiction. The system includes separate notification flows for blinded and unblinded staff to maintain protocol compliance and trial integrity.

Clearmind Medicine (Nasdaq: CMND) has reached a significant milestone as its drug candidate CMND-100 arrives in the United States, preparing for its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) treatment.

The clinical trial will evaluate CMND-100, a proprietary MEAI-based oral drug candidate, for safety and efficacy in reducing alcohol consumption. The study will be conducted at prestigious institutions including Yale School of Medicine's Department of Psychiatry, Johns Hopkins University School of Medicine, and IMCA in Ramat Gan, Israel.

The company is targeting a significant market opportunity, as AUD affects over 28 million adults in the U.S., with an estimated global market potential of $35 billion. CMND-100 aims to reduce alcohol consumption and cravings through a novel mechanism of action.

Clearmind Medicine (Nasdaq: CMND) has signed a non-binding Letter of Intent with Polyrizon (Nasdaq: PLRZ) to develop a novel intranasal formulation for its psychedelic-based treatments. The collaboration aims to enhance the delivery of Clearmind's proprietary drug candidate, 5-Methoxy-2-aminoindane (MEAI), alone or combined with Palmitoylethanolamide (PEA).

The partnership focuses on developing an intranasal delivery system that could offer several advantages including:

• Faster absorption and onset of action
• Higher bioavailability for increased therapeutic effects
• Enhanced patient compliance through non-invasive administration

Under the agreement, Clearmind will fund the R&D process, while Polyrizon will advance formulation development using its proprietary intranasal drug delivery platform. Upon successful proof of concept, the parties plan to negotiate a definitive agreement covering IP rights, commercialization, and financial terms.